All Stories

  1. Effectiveness of topical gabapentin in the treatment of vulvodynia: a narrative synthesis

    Article • Frontiers in Pain Research, July 2023, Frontiers

    Kim Lawson

  2. What is the progress of experimental drug development for fibromyalgia?

    Article • Expert Opinion on Investigational Drugs, June 2023, Taylor & Francis

    Kim Lawson

  3. Regulation of blood pressure by natural sulfur compounds: Focus on their mechanisms of action

    Article • Biochemical Pharmacology, December 2022, Elsevier

    Kim Lawson

  4. Identification of the Involvement of Potassium Channels in Fibromyalgia

    Article • Frontiers in Bioscience-Scholar, October 2022, IMR Press

    Kim Lawson

  5. Potential Effects of Natural H2S-Donors in Hypertension Management

    Article • Biomolecules, April 2022, MDPI AG

    Kim Lawson

  6. Flupirtine as a Potential Treatment for Fibromyalgia

    Article • Journal of Exploratory Research in Pharmacology, April 2021, Xia & He Publishing

    Kim Lawson

  7. Comorbid Conditions, Mental Health and Cognitive Functions in Adults with Fibromyalgia

    Article • Western Journal of Nursing Research, June 2020, SAGE Publications

    Simon Ashe, Kim Lawson

  8. Sleep Dysfunction in Fibromyalgia and Therapeutic Approach Options

    Article • January 2020, Open BioMedical Publishing Corporation

    Kim Lawson

  9. Pharmacology and clinical applications of flupirtine: Current and future options

    Article • World Journal of Pharmacology, January 2019, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Kim Lawson

  10. Is there a role for melatonin in fibromyalgia?

    Article • AIMS Molecular Science, January 2019, American Institute of Mathematical Sciences (AIMS)

    Kim Lawson

  11. Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis

    Article • World Journal of Pharmacology, October 2018, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Kim Lawson

  12. Patients’ perspective of effectiveness & acceptability of treatments of fibromyalgia

    Article • Scandinavian Journal of Pain, October 2018, De Gruyter

    Simon Ashe, Kim Lawson

  13. Flupirtine an Effective Analgesic: Is the Associated Rare Liver Injury a Limiting Factor?

    Article • Anesthesia & Analgesia, August 2018, Wolters Kluwer Health

    Kim Lawson

  14. What causes fibromyalgia? An online survey of patient perspectives

    Article • Health Psychology Open, July 2018, SAGE Publications

    Simon Ashe, Kim Lawson

  15. The experience of living with Fibromyalgia in the UK.

    Article • Health Psychology Open, July 2017, SAGE Publications

    Simon Ashe, Kim Lawson

  16. Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia

    Article • Biomedicines, May 2017, MDPI AG

    Kim Lawson

  17. Emerging pharmacological strategies for the treatment of fibromyalgia

    Article • World Journal of Pharmacology, January 2017, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Kim Lawson

  18. Potential drug therapies for the treatment of fibromyalgia

    Article • Expert Opinion on Investigational Drugs, June 2016, Taylor & Francis

    Kim Lawson

  19. Clinical Trials for Patients with Fibromyalgia Syndrome

    Article • Clinical and Experimental Pharmacology, January 2014, OMICS Publishing Group

    Kim Lawson

  20. Innovative Approaches for the Complexity of Fibromyalgia

    Article • Clinical and Experimental Pharmacology, January 2013, OMICS Publishing Group

    Kim Lawson

  21. Phasic activity of urinary bladder smooth muscle in the streptozotocin-induced diabetic rat: Effect of potassium channel modulators

    Article • European Journal of Pharmacology, June 2011, Elsevier

    Kim Lawson

  22. The role of c‐kit‐positive interstitial cells in mediating phasic contractions of bladder strips from streptozotocin‐induced diabetic rats

    Article • BJU International, August 2010, Wiley

    Kim Lawson

  23. Treatment options and patient perspectives in the management of fibromyalgia: future trends

    Article • Neuropsychiatric Disease and Treatment, November 2008, Dove Medical Press

    Kim Lawson

  24. Pharmacological treatments of fibromyalgia: Do complex conditions need complex therapies?

    Article • Drug Discovery Today, April 2008, Elsevier

    Kim Lawson

  25. Rubidium Efflux as a Tool for the Pharmacological Characterisation of Compounds with BK Channel Opening Properties

    Article • January 2008, Springer Science + Business Media

    Kim Lawson

  26. Are complex therapies required as pharmacological treatments of fibromyalgia?

    Article • Future Rheumatology, December 2007, Future Medicine

    Kim Lawson

  27. Potassium Channels as Targets for the Management of Pain

    Article • Central Nervous System Agents in Medicinal Chemistry, June 2006, Bentham Science Publishers

    Kim Lawson

  28. Increasing awareness and recognition of fibromyalgia

    Article • British Journal of Therapy and Rehabilitation, June 2003, Mark Allen Group

    Kim Lawson

  29. Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?

    Article • Expert Opinion on Investigational Drugs, October 2002, Informa Healthcare

    Kim Lawson

  30. Peripheral channelopathies as targets for potassium channel openers

    Article • Expert Opinion on Investigational Drugs, July 2001, Informa Healthcare

    Kim Lawson

  31. The Pharmacotherapy of Common Functional Syndromes

    Article • Physiotherapy, February 2001, Elsevier

    Kim Lawson

  32. Is there a role for potassium channel openers in neuronal ion channel disorders?

    Article • Expert Opinion on Investigational Drugs, October 2000, Informa Healthcare

    Kim Lawson

  33. Potassium channel openers as potential therapeutic weapons in ion channel disease

    Article • Kidney International, March 2000, Elsevier

    Kim Lawson

  34. Therapeutic Applications of Anti-depressant Drugs in Fibromyalgia Syndrome

    Article • Physiotherapy, April 1999, Elsevier

    Kim Lawson

  35. Tizanidine

    Article • Physiotherapy, September 1998, Elsevier

    Kim Lawson

  36. Is there a Therapeutic Future for ‘Potassium Channel Openers’?

    Article • Clinical Science, December 1996, Portland Press Ltd.

    Kim Lawson

  37. Potassium channel activation: A potential therapeutic approach?

    Article • Pharmacology & Therapeutics, January 1996, Elsevier

    Kim Lawson

  38. Differential effects of endothelin‐1 on the vasorelaxant properties of benzopyran and non‐benzopyran potassium channel openers

    Article • British Journal of Pharmacology, September 1992, Wiley

    Kim Lawson

  39. Contractile responses to calcium chloride in rat aortic rings bathed in K+‐free solution are resistant to organic calcium antagonists

    Article • British Journal of Pharmacology, January 1989, Wiley

    Kim Lawson